Data protection Impressum

Life sciences

The applied research partnership between CSEM, the Insel Gruppe, and the University of Bern has been extended for three years, building on 32 medtech projects launched since 2023 and reinforcing Bern's ambition to become a leading international medical hub by 2030.

CSEM, Insel Gruppe, and University of Bern extend Bern medtech collaboration for three more years

20 April 2026

ONWARD Medical has secured EUR 40.6 million through an accelerated bookbuild offering led by a EUR 25 million investment from EQT Life Sciences, extending the company's cash runway into the first quarter of 2028.

ONWARD Medical raises EUR 40 million to extend ARC therapy commercialization

20 April 2026

Lausanne-based AC Immune has amended its license and collaboration agreement with Eli Lilly to advance new Tau Morphomer small molecule candidates for Alzheimer's disease and other neurodegenerative diseases, with IND-enabling studies set to commence in the first half of 2026.

AC Immune secures CHF 10 million from Lilly to advance Alzheimer’s therapy

15 April 2026

Geneva-based dEEGtal has appointed neurotechnology entrepreneur and investor Ann Bunnenberg to its board of directors, as the AI-powered brain signal platform advances clinical studies across Switzerland, Spain, and the United States ahead of a CHF 4–5 million seed round.

dEEGtal strengthens governance and advances clinical validation across three continents

14 April 2026

Four life sciences projects were recognized at BIND – BioInnovation Day 2026, held at CHUV Lausanne on 1 April 2026, as the region's flagship academic innovation showcase drew 340 participants from academia, healthcare, industry, and investment.

BIND 2026 highlights Western Switzerland’s life sciences innovation pipeline

14 April 2026

Global in vitro diagnostics leader bioMérieux has invested over CHF 1 million in Geneva-based scale-up Plair, whose RAPID-C+ system is setting a new standard for real-time viable particle monitoring in pharmaceutical cleanrooms.

bioMérieux invests in Plair to advance environmental monitoring in pharma

30 March 2026

HeroSupport, a spin-off from the University Hospitals of Geneva, has obtained CE Mark certification for VENUS SHELL, a personalized 3D-printed breast immobilization system for prone radiotherapy.

HeroSupport receives CE Mark for its VENUS SHELL radiotherapy device

10 March 2026

Lausanne-based Polares Medical has closed an oversubscribed USD 50 million Series C financing round to advance clinical studies of its MRace Posterior Leaflet Replacement system for mitral regurgitation across the US, Europe, and Australia.

Polares Medical raises USD 50 million to advance its mitral valve replacement system

9 March 2026

Alithea Genomics has completed its seed financing round with an additional CHF 3 million, bringing the total to CHF 6.9 million, to accelerate the commercialization of its large-scale RNA sequencing platforms for drug screening and toxicology.

Alithea Genomics raises CHF 6.9 million to industrialize RNA sequencing

9 March 2026

Geneva's University Hospitals (HUG) are launching a dedicated Women's Cardiovascular Health Center to address the underdiagnosis of heart disease in women.

Geneva’s HUG launches a dedicated cardiovascular health center for women

9 March 2026

1 2 3 4 5 … 48